Please login to the form below

Not currently logged in
Email:
Password:

Hepatitis B virus

This page shows the latest Hepatitis B virus news and features for those working in and with pharma, biotech and healthcare.

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Precision’s chief scientific officer, Derek Jantz commented: "Gilead's cure-based approach to hepatitis B is comprehensive and exciting. ... He said: “Gilead is committed to developing innovative therapies to achieve functional cure for patients with

Latest news

  • Ionis must go it alone as GSK ditches polyneuropathy drug Ionis must go it alone as GSK ditches polyneuropathy drug

    GSK isn't giving up on Ionis’pipeline entirely, however. The pharma group is still developing two Ionis drugs for hepatitis B virus in phase II trials.

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    The European Commission has granted Gilead's Vemlidy European marketing authorisation, making it the first new hepatitis B virus (HBV) treatment to receive EU approval in nearly a decade. ... infectious diseases, including hepatitis B, while we continue

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    Gilead's hepatitis B virus treatment set for European approval. CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk. ... Gilead Sciences' once-daily chronic hepatitis B virus (HBV) therapy Vemlidy has been recommended for the treatment of

  • Priority FDA review for new Gilead HCV combination therapy Priority FDA review for new Gilead HCV combination therapy

    A new combination therapy for hepatitis C virus (HCV) from Gilead Sciences could be approved in the US by the summer after being awarded a priority review by the FDA. ... Meanwhile, Gilead has also reported positive news in the area of hepatitis B virus

  • J&J buys firm seeking hepatitis B cure J&J buys firm seeking hepatitis B cure

    J&J buys firm seeking hepatitis B cure. Acquires Philadelphia-based Novira therapeutics. ... Johnson &Johnson (J&J) has agreed to buy a Pennsylvania biotech company that is trying to develop treatments to cure hepatitis B virus (HBV) infection.

More from news
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers. ... These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics